Inhibition of growth, migration and invasion of human bladder cancer cells by antrocin, a sesquiterpene lactone isolated from Antrodia cinnamomea, and its molecular mechanisms

Cancer Letters

Volumn 373, Issue 2, 2016, Pages 174-184

  Chiu, Kun Yuan ^a,b,c   Wu, Chun Chi ^d,e   Chia, Chi Hao ^b,c   Hsu, Shih Lan ^a,b,c   Tzeng, Yew Min ^a,f  

^a CHAOYANG UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHI NAN UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL TAITUNG UNIVERSITY   (Taiwan)

Author keywords

Antrocin; Bladder cancer; EMT; FAK; Invasion

Indexed keywords

ANTROCIN; CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; FOCAL ADHESION KINASE; GELATINASE A; HLA DR5 ANTIGEN; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PAXILLIN; PROTEIN BAX; PROTEIN C FOS; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; CADHERIN; LACTONE; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; ANTRODIA CINNAMOMEA; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENHANCER REGION; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FILOPODIUM; FOCAL ADHESION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ISOLATION PROCEDURE; LAMELLIPODIUM; METASTASIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LACTONES; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; PAXILLIN; PROTO-ONCOGENE PROTEINS C-FOS; SESQUITERPENES; URINARY BLADDER NEOPLASMS;

EID: 84958674264     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.046     Document Type: Article

References (69)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61(2):69-90.
2. Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol 2013, 63(2):234-241.
3. Brausi M., Witjes J.A., Lamm D., Persad R., Palou J., Colombel M., et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J. Urol 2011, 186(6):2158-2167.
4. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006, 27(3):361-373.
5. Skeldon S.C., Larry Goldenberg S. Bladder cancer: a portal into men's health. Urologic Oncology: Seminars and Original Investigations 2014, Elsevier.
6. Yamaguchi H., Wyckoff J., Condeelis J. Cell migration in tumors. Curr. Opin. Cell Biol 2005, 17(5):559-564.
7. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3(5):362-374.
8. Nabeshima K., Inoue T., Shimao Y., Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Int 2002, 52(4):255-264.
9. Hsia D.A., Mitra S.K., Hauck C.R., Streblow D.N., Nelson J.A., Ilic D., et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol 2003, 160(5):753-767.
10. Sulzmaier F.J., Jean C., Schlaepfer D.D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer 2014, 14:598-610.
11. Zhao X., Guan J.-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev 2011, 63(8):610-615.
12. Bagi C.M., Roberts G.W., Andresen C.J. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors. Cancer 2008, 112(10):2313-2321.
13. Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C., et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008, 68(6):1935-1944.
14. Slack-Davis J.K., Hershey E.D., Theodorescu D., Frierson H.F., Parsons J.T. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol. Cancer Ther 2009, 8(8):2470-2477.
15. Tan W., Lu J., Huang M., Li Y., Chen M., Wu G., et al. Anti-cancer natural products isolated from chinese medicinal herbs. Chin. Med 2011, 6(1):27.
16. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod 2012, 75(3):311-335.
17. Geethangili M., Tzeng Y.-M. Review of pharmacological effects of Antrodia camphorata and its bioactive compounds. Evid. Based Complement. Alternat. Med 2011, 2011:212641.
18. Geethangili M., Rao Y.K., Tzeng Y.-M. Development and validation of a HPLC-DAD separation method for determination of bioactive antrocin in medicinal mushroom Antrodia camphorata. Int. J. Appl. Sci. Eng 2013, 11(2):195-201.
19. Rao Y.K., Wu A.T., Geethangili M., Huang M.T., Chao W.J., Wu C.H., et al. Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. Chem. Res. Toxicol 2011, 24(2):238-245.
20. Yeh C.-T., Huang W.C., Rao Y.K., Ye M., Lee W.H., Wang L.S., et al. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells. Carcinogenesis 2013, 34:2918-2928.
21. Lin T.C., Lee T.C., Hsu S.L., Yang C.S. The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast. PLoS ONE 2011, 6(2):e16654.
22. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
23. Zhao J., Guan J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009, 28(1-2):35-49.
24. Webb D.J., Donais K., Whitmore L.A., Thomas S.M., Turner C.E., Parsons J.T., et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat. Cell Biol 2004, 6(2):154-161.
25. Panetti T.S. Tyrosine phosphorylation of Paxillin, FAK, and p130Cas: effects on cell spreading and migration. Front. Biosci 2002, 7:143-150.
26. Sumagin R., Robin A., Nusrat A., Parkos C.A. Activation of PKCβII by PMA facilitates enhanced epithelial wound repair through increased cell spreading and migration. PLoS ONE 2013, 8(2):e55775.
27. Arjonen A., Kaukonen R., Ivaska J. Filopodia and adhesion in cancer cell motility. Cell Adh. Migr 2011, 5(5):421-430.
28. Leventhal P.S., Shelden E.A., Kim B., Feldman E.L. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-i-stimulated lamellipodial advance. J. Biol. Chem 1997, 272:5214-5218.
29. Zaidel-Bar R., Ballestrem C., Kam Z., Geiger B. Early molecular events in the assembly of matrix adhesions at the leading edge of migrating cells. J. Cell Sci 2003, 116:4605-4613.
30. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front. Biosci 2005, 11:479-491.
31. Chen Y.J., Wei Y.Y., Chen H.T., Fong Y.C., Hsu C.J., Tsai C.H., et al. Osteopontin increases migration and MMP-up-regulation via αvβ3 integrin, FAK, ERK, and NF-κB-dependent pathway in human chondrosarcoma cells. J. Cell. Physiol 2009, 221(1):98-108.
32. Xu H.-Y., Qian A.R., Shang P., Xu J., Kong L.M., Bian H.J., et al. siRNA targeted against HAb18G/CD147 inhibits MMP-secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. Cancer Lett 2007, 247(2):336-344.
33. Chen Y.J., Chang L.S. Gallic acid downregulates matrix metalloproteinase-(MMP-2) and MMP-in human leukemia cells with expressed Bcr/Abl. Mol. Nutr. Food Res 2012, 56(9):1398-1412.
34. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol 2006, 172(7):973-981.
35. Chatzizacharias N.A., Kouraklis G.P., Theocharis S.E. Clinical significance of FAK expression in human neoplasia. Histol. Histopathol 2008, 23(5):629-650.
36. van Nimwegen M.J., van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem. Pharmacol 2007, 73(5):597-609.
37. Deramaudt T.B., Dujardin D., Hamadi A., Noulet F., Kolli K., De Mey J., et al. FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol. Biol. Cell 2011, 22(7):964-975.
38. Deramaudt T.B., Dujardin D., Noulet F., Martin S., Vauchelles R., Takeda K., et al. Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes. PLoS ONE 2014, 9(3):e92059.
39. Mattila P.K., Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat. Rev. Mol. Cell Biol 2008, 9(6):446-454.
40. Leventhal P.S., Shelden E.A., Kim B., Feldman E.L. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J. Biol. Chem 1997, 272(8):5214-5218.
41. Guan J.L. Role of focal adhesion kinase in integrin signaling. Int. J. Biochem. Cell Biol 1997, 28(8-9):1085-1096.
42. Hiscox S., Barnfather P., Hayes E., Bramble P., Christensen J., Nicholson R.I., et al. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Res. Treat 2011, 125(3):659-669.
43. Schlaepfer D.D., Jones K.C., Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol. Cell. Biol 1998, 18(5):2571-2585.
44. Chaturvedi L.S., Gayer C.P., Marsh H.M., Basson M.D. Repetitive deformation activates Src-independent FAK-dependent ERK motogenic signals in human Caco-intestinal epithelial cells. Am. J. Physiol. Cell Physiol 2008, 294(6):1350-1361.
45. Cary L.A., Guan J.L. Focal adhesion kinase in integrin-mediated signaling. Front. Biosci 1999, 154(4):102-113.
46. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol 1999, 71(3-4):435-478.
47. Schlaepfer D.D., Mitra S.K., Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim. Biophys. Acta 2004, 1692(2-3):77-102.
48. Hu B., Jarzynka M.J., Guo P., Imanishi Y., Schlaepfer D.D., Cheng S.Y. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res 2006, 66(2):775-783.
49. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol 2006, 18(5):516-523.
50. Robins H.I., O'Neill A., Gilbert M., Olsen M., Sapiente R., Berkey B., et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother. Pharmacol 2008, 62(2):227-233.
51. Bauvois B. New facets of matrix metalloproteinases MMP-and MMP-as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 2012, 1825(1):29-36.
52. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarker s and potential therapeutic targets in human cancer. J. Clin. Oncol 2009, 27(31):5287-5297.
53. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278(1):16-27.
54. Szarvas T., vom Dorp F., Ergün S., Rübben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat. Rev. Urol 2011, 8(5):241-254.
55. Kumar B., Koul S., Petersen J., Khandrika L., Hwa J.S., Meacham R.B., et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-and MMP-activity. Cancer Res 2010, 70(2):832-841.
56. Lin H.-J., Su C.C., Lu H.F., Yang J.S., Hsu S.C., Ip S.W., et al. Curcumin blocks migration and invasion of mouse-rat hybrid retina ganglion cells (N18) through the inhibition of MMP-2,-9, FAK, Rho A and Rock-gene expression. Oncol. Rep 2010, 23(3):665.
57. Gong Y., Chippada-Venkata U.D., Oh W.K. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel) 2014, 6(3):1298-1327.
58. Bian J., Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol 1997, 17(11):6330-6338.
59. Bergman M., Cheng S., Honbo N., Piacentini L., Karliner J.S., Lovett D.H. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem. J. 2003, 369:485-496.
60. Qin H., Sun Y., Benveniste E.N. The transcription factors Sp1, Sp3, and AP-are required for constitutive matrix metalloproteinase-gene expression in astroglioma cells. J. Biol. Chem 1999, 274(41):29130-29137.
61. Staun-Ram E., Goldman S., Shalev E. Ets-and p53 mediate cAMP-induced MMP-expression, activity and trophoblast invasion. Reprod. Biol. Endocrinol 2009, 7(1):135.
62. O'Donnell A., Odrowaz Z., Sharrocks A. Immediate-early gene activation by the MAPK pathways: what do and don't we know?. Biochem. Soc. Trans 2012, 40(1):58-66.
63. Son H., Moon A. Epithelial-mesenchymal transition and cell invasion. Toxicol. Res 2010, 26(4):245-252.
64. Jeanes A., Gottardi C.J., Yap A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27(55):6920-6929.
65. Slaton J.W., Karashima T., Perrotte P., Inoue K., Kim S.J., Izawa J., et al. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res 2001, 7(9):2840-2853.
66. Bryan R.T., Tselepis C. Cadherin switching and bladder cancer. J. Urol 2010, 184(2):423-431.
67. Gilles C., Polette M., Piette J., Delvigne A.C., Thompson E.W., Foidart J.M., et al. Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J. Pathol 1996, 180(2):175-180.
68. Thomas P.A., Kirschmann D.A., Cerhan J.R., Folberg R., Seftor E.A., Sellers T.A., et al. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin. Cancer Res 1999, 5(10):2698-2703.
69. McInroy L., Määttä A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem. Biophys. Res. Commun 2007, 360(1):109-114.